Evaluation of Safety, Tolerability, Immunogenicity and Efficacy of a Novel Method in Specific Immunotherapy in Cat Allergic Patients: a Placebo Controlled Trial

Phase 1

Completed

• Conditions: Allergy to Cat Dander
• Interventions: Drug: Placebo; Drug: IVN201

• Registration Number: NCT00718679
• Lead Sponsor: University of Zurich

Brief Summary

This study is placebo controlled, double blind, randomised, two arm dose escalation of a new product for specific immunotherapy in cat allergic patients

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07
• Study First Submitted: 2008-07-18
• Study First Submitted QC: 2008-07-18
• Study First Posted: 2008-07-21
• Status Verified: 2010-02
• Primary Completion: 2010-02
• Study Completion: 2010-02
• Last Update Submitted: 2010-02-10
• Last Update Posted: 2010-02-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	Placebo	Placebo
1	IVN201	Study drug

Primary Outcome Measures

Name	Time	Method
Saftety tolerability and efficacy	2009

Trial Locations

Locations (1)

Center for Clinical Research University Hospital Zurich; 🇨🇭 Zurich, Switzerland